Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers - Trial NCT06395610
Access comprehensive clinical trial information for NCT06395610 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chiesi Farmaceutici S.p.A. and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chiesi Farmaceutici S.p.A.
Timeline & Enrollment
Phase 1
Mar 28, 2024
Jul 27, 2024
Primary Outcome
Pharmacokinetic parameter (AUC0-t),Pharmacokinetic parameter (Cmax)
Summary
The objective of this study is to investigate the effect of the interaction of Erythromycin
 (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in
 Healthy Volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06395610
Non-Device Trial